FolioStart free

Medicine · Literature

Research papers on Cancer immunotherapy

Recent and highly-cited academic work on cancer immunotherapy, gathered from Semantic Scholar, CrossRef and OpenAlex.

Search all 200M+ papers on this topic, free →

  1. PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

    Andreas D. Hartkopf, Florin‐Andrei Taran, Markus Wallwiener, et al. · 2016 · Breast Care · 30,919 citations

    Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.

  2. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

    Rimda Wanchoo, Sabine Karam, Nupur N. Uppal, et al. · 2017 · American Journal of Nephrology · 15,288 citations

    BACKGROUND: Cancer immunotherapy, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death 1 (PD-1), has revolutionized the treatment of malignancies by engaging the patient's own immune system against the tumor rather than targeting the cancer directly. These therapies have demonstrated a significant benefit in the treatment of melanomas and other cancers. SUMMARY: In order to provide an extensive overview of the renal toxicities induced by these agents, a Medline search was conducted of published literature related to ipilimumab-, pembrolizumab-, and nivolumab-induced kidney toxicity. In addition, primary data from the initial clinical trials of these age

  5. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Igor Puzanov, Adi Diab, et al. · 2017 · Journal for ImmunoTherapy of Cancer · 1,995 citations

    Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the same immunologic mechanisms responsible for the drugs' therapeutic effects, namely blockade of inhibitory mechanisms that suppress the immune system and protect body tissues from an unconstrained acute or chronic immune response. Skin, gut, endocrine, lung and musculoskeletal irAEs are relatively common, whereas cardiovascular, hematologic, renal, neurologic and ophthalmologic irAEs occur much less f

  6. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

    Alyson Haslam, Vinay Prasad · 2019 · JAMA Network Open · 1,428 citations

    Importance: Immunotherapy checkpoint inhibitors have generated considerable interest because of durable responses in a number of hitherto intractable tumor types. Objective: To estimate the percentage of patients with cancer in the United States who are eligible for and respond to checkpoint inhibitor drugs approved for oncology indications by the US Food and Drug Administration (FDA). Design, Setting, and Participants: Retrospective cross-sectional study performed from June 2018 through October 2018 using publicly available data to determine (1) demographic characteristics of patients with advanced or metastatic cancer, (2) FDA data on checkpoint inhibitors approved from January 2011 throug

  7. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

    Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, et al. · 2021 · Journal for ImmunoTherapy of Cancer · 842 citations

    Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in cl

  8. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

    Julianne D. Twomey, Baolin Zhang · 2021 · The AAPS Journal · 666 citations

    Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many cancer indications. This review provides an update on ICIs approved by the Food and Drug Administration (FDA), with focus on monoclonal antibodies that target the programmed cell death 1 (PD-1) or its ligand, PD-1 ligand 1 (PD-L1), including information on their clinical indications and associated companion diagnostics. The information is further discussed with strategies for identifying predictive biomarkers to guide the clinical use of PD-1/PD-L1-targeted therapies.

  11. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors

    Rilan Bai, Zheng Lv, Dongsheng Xu, et al. · 2020 · Biomarker Research · 478 citations

    Although the clinical development of immune checkpoint inhibitors (ICIs) therapy has ushered in a new era of anti-tumor therapy, with sustained responses and significant survival advantages observed in multiple tumors, most patients do not benefit. Therefore, more and more attention has been paid to the identification and development of predictive biomarkers for the response of ICIs, and more in-depth and comprehensive understanding has been continuously explored in recent years. Predictive markers of ICIs efficacy have been gradually explored from the expression of intermolecular interactions within tumor cells to the expression of various molecules and cells in tumor microenvironment, and

  13. Immune Checkpoint Inhibitors Therapy in Prostate Cancer: Lessons Learnt

    Meena Chandok · 2020 · Annals of Immunology & Immunotherapy · 3 citations

    Immune checkpoint inhibitors (ICIs) therapy has rapidly changed the treatment landscape for a number of cancers but resulted in only marginal success in prostate cancer (PCa). In order to bring about durable clinical benefit of immune check point inhibitor therapy in prostate cancer, it is critical to understand the current status of ICIs therapy for PCa and reasons for low/negligible outcomes. This article summarizes the current status of ICIs therapy in PCa and discusses how ICIs therapy can result in the successful treatment of a specific subset of PCa patients. In this article, we review how immunotherapy and different combination therapies are paving their way by incorporating the strat

  14. Immunotherapy Breakthrough: Immune Checkpoint Inhibitors in Cancer Treatment

    Zewei Yu · 2024 · Highlights in Science, Engineering and Technology · 3 citations

    Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, offering new possibilities for patients with various malignancies. This review examines the molecular mechanisms of immune checkpoints (ICs), particularly the PD-1/PD-L1 and CTLA-4 pathways, and their roles in tumor immune evasion. Major ICIs, including anti-PD-1/PD-L1 and anti-CTLA-4 drugs, are discussed, with emphasis on their effectiveness in treating both solid and hematological cancers. The review also explores combination treatment strategies that aim to improve therapeutic outcomes. Despite considerable progress, challenges such as drug resistance and immune-related adverse events (irAEs) remain. These issues are a

  18. CURRENT PROGRESS IN IMMUNE CHECKPOINT INHIBITORS FOR CANCER IMMUNOTHERAPY: A POST EVENT REPORT OF ICI2017

    Wenda Gao · 2018 · Immunology and Inflammation Diseases Therapy

    Tumor immunotherapy has entered a phase of rapid development with a shift in emphasis away from classical vaccination approaches against tumor-associated antigens (TAA) towards a focus on various strategies to modify the functions of T cells, as well as to understand and modulate the immunosuppressive nature of tumor microenvironment (TME). With such a paradigm shift, recent international conferences such as "Immune Checkpoint Inhibitors (ICI) Boston" provided unparalleled depth of insights on factors that influence combination efficacy, role of TME, identification of translational biomarkers, latest preclinical modeling approaches, as well as the scientific rationale of targeting novel immu

  21. Combinational cancer immunotherapy: Allergy-assisted immunotherapy and immune checkpoint inhibitors

    Michael John Dochniak · 2025 · GSC Biological and Pharmaceutical Sciences

    Allergy-assisted cancer immunotherapy is an innovative approach that leverages the body's natural immune response to allergies. This approach potentially enhances the effectiveness of cancer immunotherapy by stimulating the immune system and improving its ability to inhibit malignant tumors. This review discusses combinational therapy wherein immune checkpoint inhibitors (i.e., immunologic adjuvants) are part of allergy-assisted cancer immunotherapy.

Write your paper with these sources

Folio is the integrity-first research workspace: search 200M+ papers, save sources, and write with citations that format themselves. Free for students and researchers.

Start writing free →